Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Kraig Biocraft Laboratories (KBLB) Shares Outstanding (Weighted Average) (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $976.6 million as the latest value for Q3 2022.

  • Quarterly Shares Outstanding (Weighted Average) rose 12.82% to $976.6 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $976.6 million through Sep 2022, up 12.82% year-over-year, with the annual reading at $877.6 million for FY2021, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) hit $976.6 million in Q3 2022 for Kraig Biocraft Laboratories, up from $949.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $976.6 million in Q3 2022 to a low of $816.8 million in Q1 2018.
  • Historically, Shares Outstanding (Weighted Average) has averaged $863.4 million across 4 years, with a median of $847.5 million in 2019.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 0.63% in 2019 and later rose 12.82% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $816.9 million in 2018, then rose by 2.81% to $839.8 million in 2019, then increased by 4.5% to $877.6 million in 2021, then rose by 11.28% to $976.6 million in 2022.
  • Business Quant data shows Shares Outstanding (Weighted Average) for KBLB at $976.6 million in Q3 2022, $949.5 million in Q2 2022, and $939.5 million in Q1 2022.